ATAI
Price
$1.21
Change
+$0.02 (+1.68%)
Updated
Dec 20, 04:59 PM (EDT)
94 days until earnings call
FATE
Price
$1.69
Change
+$0.03 (+1.81%)
Updated
Dec 20, 04:59 PM (EDT)
70 days until earnings call
Ad is loading...

ATAI vs FATE

Header iconATAI vs FATE Comparison
Open Charts ATAI vs FATEBanner chart's image
ATAI Life Sciences
Price$1.21
Change+$0.02 (+1.68%)
Volume$42.26K
CapitalizationN/A
Fate Therapeutics
Price$1.69
Change+$0.03 (+1.81%)
Volume$97.27K
CapitalizationN/A
ATAI vs FATE Comparison Chart
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. FATE commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and FATE is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ATAI: $1.19 vs. FATE: $1.68)
Brand notoriety: ATAI and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 151% vs. FATE: 307%
Market capitalization -- ATAI: $199.68M vs. FATE: $192.48M
ATAI [@Biotechnology] is valued at $199.68M. FATE’s [@Biotechnology] market capitalization is $192.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATAI and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • ATAI’s TA Score: 4 bullish, 6 bearish.
  • FATE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than FATE.

Price Growth

ATAI (@Biotechnology) experienced а -12.50% price change this week, while FATE (@Biotechnology) price change was -8.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ATAI is expected to report earnings on Mar 27, 2025.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($200M) and FATE($192M) have the same market capitalization . ATAI YTD gains are higher at: -15.603 vs. FATE (-55.080). ATAI has higher annual earnings (EBITDA): -124.33M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. ATAI (85.9M). ATAI has less debt than FATE: ATAI (23.8M) vs FATE (99M). FATE has higher revenues than ATAI: FATE (13.4M) vs ATAI (331K).
ATAIFATEATAI / FATE
Capitalization200M192M104%
EBITDA-124.33M-177.57M70%
Gain YTD-15.603-55.08028%
P/E RatioN/AN/A-
Revenue331K13.4M2%
Total Cash85.9M297M29%
Total Debt23.8M99M24%
FUNDAMENTALS RATINGS
ATAI vs FATE: Fundamental Ratings
ATAI
FATE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
8194
P/E GROWTH RATING
1..100
15100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for ATAI (78) in the Miscellaneous Commercial Services industry. This means that FATE’s stock grew somewhat faster than ATAI’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATAI (100) in the Miscellaneous Commercial Services industry. This means that FATE’s stock grew similarly to ATAI’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as ATAI (98) in the Miscellaneous Commercial Services industry. This means that FATE’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (81) in the Miscellaneous Commercial Services industry is in the same range as FATE (94) in the Biotechnology industry. This means that ATAI’s stock grew similarly to FATE’s over the last 12 months.

ATAI's P/E Growth Rating (15) in the Miscellaneous Commercial Services industry is significantly better than the same rating for FATE (100) in the Biotechnology industry. This means that ATAI’s stock grew significantly faster than FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAIFATE
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIQX11.810.06
+0.54%
Fidelity Advisor Real Estate Income M
HSMVX13.670.06
+0.44%
Hartford Small Cap Value R6
RYPRX10.920.04
+0.37%
Royce Premier Invmt
RBCIX8.620.02
+0.23%
RBC China Equity I
MPLAX13.09N/A
N/A
Praxis International Index A

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with FATE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
N/A
FATE - ATAI
48%
Loosely correlated
+1.20%
COUR - ATAI
45%
Loosely correlated
-1.07%
VCYT - ATAI
45%
Loosely correlated
+4.66%
ALLO - ATAI
45%
Loosely correlated
+1.63%
NTLA - ATAI
45%
Loosely correlated
+0.83%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.20%
ALLO - FATE
58%
Loosely correlated
+1.63%
RCKT - FATE
51%
Loosely correlated
+1.85%
CRBU - FATE
51%
Loosely correlated
-0.55%
CCCC - FATE
50%
Loosely correlated
+2.73%
BEAM - FATE
50%
Loosely correlated
+8.04%
More